M 4 E Common Technical Document for the …
European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: mail@emea.eu.int http://www ...
Download M 4 E Common Technical Document for the …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
DOSE-RESPONSE INFORMATION TO SUPPORT …
www.ich.orgDose-Response Information to Support Drug Registration steps, and maximum recommended dose, based on different perceptions of risk/benefit relationships.
Overview of Drug Development - ICH
www.ich.orgThe information within this presentation is based on the presenter’s expertise and experience, and represents the views of the presenter for …
G u id an ce o n d os e leve l select ion fo r reg …
www.lasa.co.ukThe 3Rs: Replacement refers to methods that replace or avoid the use of animals in areaswhere animals would have otherwise been used Reduction refers to methods which minimise animal use and enable researchers to obtain comparable levels of information from fewer animals or
Medicines Control Council
www.mccza.comRegistration of Medicines Reporting of Post-Marketing ADRs 2.33_ADR_reporting_post-marketing_Jul16_v4.1_showing_changes.doc Nov 2016 Page 4 of 22 Back to ToC
Pharmacovigilance guidelines Nov 2009 - Botswana
www.moh.gov.bw5 2 REPORTING OF ADVERSE DRUG REACTION Spontaneous reporting of suspected adverse drug reactions is the major source of information in pharmacovigilance.
SERVICE REQUEST FORM KRYSTEXXAConnect
www.krystexxahcp.comPatient: 6. DIAGNOSIS AND THERAPY INFORMATION 5. PRIOR AUTHORIZATION ASSISTANCE Please provide chart notes or other clinical information for PA support. 4. INFUSION FACILITY INFORMATION Primary Diagnosis: M1A.xxx0 – …